Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Aging, Exercise, and Hormonal Influences of Fat Metabolism

20 de enero de 2009 actualizado por: US Department of Veterans Affairs
The purpose of this study is to determine whether exercise alters the way in which the body stores and breaks down fat. A second objective is to evaluate how these effects are influenced by your age and gender. These studies are important because aging, male gender, and menopause are associated with an increased storage of abdominal fat which is frequently accompanied by diabetes, a high blood cholesterol level, high blood pressure and greater risks of heart attack, stroke, and death. Increasing evidence suggests that these abnormalities and many other effects of aging may be partly due to lack of exercise.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

The physiologic cause(s) of the age-related increase in total body and abdominal fat mass are not well-understood. The purpose of this study is to determine whether aging is associated with decreased whole body lipolytic and other metabolic responses to epinephrine and insulin, whether these responses may be augmented by exercise training or in older women by estrogen administration and to investigate whether such metabolic changes are related to reductions in abdominal adiposity. Our objectives in this project are as follows: (1) to characterize age and gender differences in lipolysis and other aspects of metabolism at rest and during graded dose epinephrine infusion with or without a pancreatic islet clamp in healthy non-obese men and women aged 20-40 and 55-75 years, (2) to evaluate relationships between metabolic responses to epinephrine or insulin and portally and nonportally-drained visceral and subcutaneous adipose tissue mass in these individuals, (3) to delineate the effects of acute and chronic exercise on lipolytic and other metabolic responses to epinephrine and insulin and on adipose tissue distribution in healthy younger and older men and women, and (4) to investigate whether 7 days and 12 months or estrogen and cyclic progesterone replacement therapy or placebo in healthy 55-75 year old women alter lipolytic and other metabolic responses to epinephrine and insulin and adipose tissue distribution.

The rates of lipolysis, oxygen uptake, fat and carbohydrate oxidation, and total triglyceride-free fatty acid (FFA) substrate cycling will be determined by indirect calorimetry and by gas chromatography-mass spectrometric analyses of blood samples obtained during infusions of the stable isotope tracers [D5] glycerol and [1 -13C] palmitate in the baseline state, during a pancreatic islet clamp in half of all male and female participants, and in all participants during a subsequent 4-stage graded dose epinephrine infusion. These data will be expressed in relation to total body wieght, fat mass, and fat-free mass, assessed from measurements of body density made by hydrostatic weighing. Adipose tissue distribution will be characterized by determination of the cross-sectional area and volume of portally and nonportally-drained visceral and subcutaneous fat deposits identified by radiographic density criteria on computed tomographic scans obtained at the level of the nipple, umbilicus, gluteal region, and midthigh. Insulin action on glucose disposal will be assessed during a hyperinsulinemic euglycemic clamp. Age and gender differences and their interactions with exercise and the plasma epinephrine concentration in the baseline state and during submaximally and maximally stimulating rates of epinephrine infustion will be evaluated by analysis of variance and covariance. Relationships between effects of estrogen treatment or exercise of adipose tissue distribution and responses to epinephrine and insulin will be assessed by multiple regression analysis.

We hypothesize that increased age will be associated with lower epinephrine-induced rates of lipolysis, fat oxidation, and triglyceride-FFA substrate cycling and decreased insulin action in both men and women when expressed in relation to total fat mass. We further hypothesize that these age-related differences will be at least partly ameliorated by exercise training and by treatment with estrogen in conjunction with a decrease in visceral abdominal and total body adiposity.

Tipo de estudio

Intervencionista

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Missouri
      • St. Louis, Missouri, Estados Unidos, 63125
        • VA Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Descripción

  • Healthy men or women between the ages of 20 and 75

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de junio de 1994

Finalización del estudio

1 de junio de 2001

Fechas de registro del estudio

Enviado por primera vez

30 de diciembre de 2004

Primero enviado que cumplió con los criterios de control de calidad

30 de diciembre de 2004

Publicado por primera vez (Estimar)

31 de diciembre de 2004

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

21 de enero de 2009

Última actualización enviada que cumplió con los criterios de control de calidad

20 de enero de 2009

Última verificación

1 de diciembre de 2004

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • ENDO-050-95S

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Enfermedad cardiovascular

3
Suscribir